Literature DB >> 21839183

Finding a better path to drug selectivity.

Yuko Kawasaki1, Ernesto Freire.   

Abstract

Extremely high affinity and selectivity are two of the most sought-after properties of drug molecules. Selectivity has been difficult to achieve, especially for targets that belong to large families of structurally and functionally related proteins. There are essentially two ways by which selectivity can be improved during lead optimization: a chemical modification of the lead compound that improves the affinity towards the target to a higher extent than to off-target molecules; and a chemical modification that lowers the affinity of the lead compound towards off-target molecules. Maximal selectivity is achieved when both mechanisms can be combined synergistically. As we discuss here, analysis of several protease inhibitors that vary in a single functionality indicates that nonpolar functionalities preferentially follow the first mechanism, whereas polar functionalities follow the second, and that those features are imprinted in their thermodynamic signatures. Copyright Â
© 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21839183      PMCID: PMC3210374          DOI: 10.1016/j.drudis.2011.07.010

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  21 in total

Review 1.  Structural biology in drug design: selective protein kinase inhibitors.

Authors:  Giovanna Scapin
Journal:  Drug Discov Today       Date:  2002-06-01       Impact factor: 7.851

Review 2.  Adaptive inhibitors of the HIV-1 protease.

Authors:  Hiroyasu Ohtaka; Ernesto Freire
Journal:  Prog Biophys Mol Biol       Date:  2005-06       Impact factor: 3.667

3.  Some binding-related drug properties are dependent on thermodynamic signature.

Authors:  Arne Schön; Navid Madani; Amos B Smith; Judith M Lalonde; Ernesto Freire
Journal:  Chem Biol Drug Des       Date:  2011-02-02       Impact factor: 2.817

4.  Compensating enthalpic and entropic changes hinder binding affinity optimization.

Authors:  Virginie Lafont; Anthony A Armstrong; Hiroyasu Ohtaka; Yoshiaki Kiso; L Mario Amzel; Ernesto Freire
Journal:  Chem Biol Drug Des       Date:  2007-06       Impact factor: 2.817

5.  Overcoming roadblocks in lead optimization: a thermodynamic perspective.

Authors:  Adam J Ruben; Yoshiaki Kiso; Ernesto Freire
Journal:  Chem Biol Drug Des       Date:  2006-01       Impact factor: 2.817

Review 6.  Adding calorimetric data to decision making in lead discovery: a hot tip.

Authors:  John E Ladbury; Gerhard Klebe; Ernesto Freire
Journal:  Nat Rev Drug Discov       Date:  2009-12-04       Impact factor: 84.694

7.  Evaluation of linked protonation effects in protein binding reactions using isothermal titration calorimetry.

Authors:  B M Baker; K P Murphy
Journal:  Biophys J       Date:  1996-10       Impact factor: 4.033

8.  Isothermal titration calorimetry: controlling binding forces in lead optimization.

Authors:  Ernesto Freire
Journal:  Drug Discov Today Technol       Date:  2004-12

9.  Azaindoles: moderately basic P1 groups for enhancing the selectivity of thrombin inhibitors.

Authors:  Philip E J Sanderson; Matthew G Stanton; Bruce D Dorsey; Terry A Lyle; Colleen McDonough; William M Sanders; Kelly L Savage; Adel M Naylor-Olsen; Julie A Krueger; S Dale Lewis; Bobby J Lucas; Joseph J Lynch; Youwei Yan
Journal:  Bioorg Med Chem Lett       Date:  2003-03-10       Impact factor: 2.823

Review 10.  Do enthalpy and entropy distinguish first in class from best in class?

Authors:  Ernesto Freire
Journal:  Drug Discov Today       Date:  2008-08-26       Impact factor: 7.851

View more
  25 in total

1.  Anticancer mechanisms of Strobilanthes crispa Blume hexane extract on liver and breast cancer cell lines.

Authors:  Rhun Yian Koh; Foong Ping Lim; Leslie Siing Yie Ling; Catherine Pei Ling Ng; Siew Foong Liew; Mei Yeng Yew; Yee Lian Tiong; Anna Pick Kiong Ling; Soi Moi Chye; Khuen Yen Ng
Journal:  Oncol Lett       Date:  2017-08-24       Impact factor: 2.967

2.  Design, Optimization, and Study of Small Molecules That Target Tau Pre-mRNA and Affect Splicing.

Authors:  Jonathan L Chen; Peiyuan Zhang; Masahito Abe; Haruo Aikawa; Liying Zhang; Alexander J Frank; Timothy Zembryski; Christopher Hubbs; HaJeung Park; Jane Withka; Claire Steppan; Lucy Rogers; Shawn Cabral; Martin Pettersson; Travis T Wager; Matthew A Fountain; Gavin Rumbaugh; Jessica L Childs-Disney; Matthew D Disney
Journal:  J Am Chem Soc       Date:  2020-05-04       Impact factor: 15.419

3.  Kinetic and thermodynamic rationale for suberoylanilide hydroxamic acid being a preferential human histone deacetylase 8 inhibitor as compared to the structurally similar ligand, trichostatin a.

Authors:  Raushan K Singh; Naveena Lall; Travis S Leedahl; Abigail McGillivray; Tanmay Mandal; Manas Haldar; Sanku Mallik; Gregory Cook; D K Srivastava
Journal:  Biochemistry       Date:  2013-10-31       Impact factor: 3.162

Review 4.  Biophysical Approaches for the Characterization of Protein-Metabolite Interactions.

Authors:  Anja Thalhammer; Nina K Bröker
Journal:  Methods Mol Biol       Date:  2023

5.  Enthalpy screen of drug candidates.

Authors:  Arne Schön; Ernesto Freire
Journal:  Anal Biochem       Date:  2016-08-25       Impact factor: 3.365

6.  Bisubstrate Inhibitors of Biotin Protein Ligase in Mycobacterium tuberculosis Resistant to Cyclonucleoside Formation.

Authors:  Ce Shi; Divya Tiwari; Daniel J Wilson; Christopher L Seiler; Dirk Schnappinger; Courtney C Aldrich
Journal:  ACS Med Chem Lett       Date:  2013-12-12       Impact factor: 4.345

7.  Application of the quantum mechanical IEF/PCM-MST hydrophobic descriptors to selectivity in ligand binding.

Authors:  Tiziana Ginex; Jordi Muñoz-Muriedas; Enric Herrero; Enric Gibert; Pietro Cozzini; F Javier Luque
Journal:  J Mol Model       Date:  2016-05-17       Impact factor: 1.810

8.  Drug-binding energetics of human α-1-acid glycoprotein assessed by isothermal titration calorimetry and molecular docking simulations.

Authors:  Johnny X Huang; Matthew A Cooper; Mark A Baker; Mohammad A K Azad; Roger L Nation; Jian Li; Tony Velkov
Journal:  J Mol Recognit       Date:  2012-12       Impact factor: 2.137

9.  A novel viral thymidylate kinase with dual kinase activity.

Authors:  Eduardo Guevara-Hernandez; Aldo A Arvizu-Flores; Maria E Lugo-Sanchez; Enrique F Velazquez-Contreras; Francisco J Castillo-Yañez; Luis G Brieba; Rogerio R Sotelo-Mundo
Journal:  J Bioenerg Biomembr       Date:  2015-08-28       Impact factor: 3.853

10.  Drug development for the irritable bowel syndrome: current challenges and future perspectives.

Authors:  Fabrizio De Ponti
Journal:  Front Pharmacol       Date:  2013-02-01       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.